November 19, 2025

Cognitive Function and Statin Administration During Doxorubicin-Based Cancer Treatment

Contrary to previous research, a preplanned secondary analysis of the multicenter PREVENT trial, reported by W.Gregory Hundley, MD, FACC, of Pauley Heart Center, Division of Cardiology, Department of ...

The ASCO Post

November 19, 2025

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

On November 6, 2025, the U.S. Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with high-risk smoldering multiple myeloma.

The ASCO Post

November 19, 2025

New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets

Using a computational tool, DeepTarget, physicians were able to predict both primary and secondary targets of small-molecule agents for cancer treatment, according to findings from a study published i...

The ASCO Post

November 19, 2025

New Study Explores Why Male Patients With AML May Have Worse Outcomes

New research has ruled out hormone signaling as the reason why men with AML tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy—a finding that helps refine ...

The ASCO Post

November 19, 2025

Project ASCENT: Advancing Lung Cancer Screening in Hispanic Populations

Lung cancer remains the leading cause of cancer mortality in the United States, surpassing the combined deaths of breast, colon and prostate cancers.

Baptist Health South Florida

November 18, 2025

This Week’s Biopharma News: New Restrictions on Sarepta Gene Therapy

Our latest news roundup reports on the FDA’s new “plausible mechanism” pathway, Novartis’s phase III malaria trial, a new gene therapy in Europe, and more.

The Medicine Maker

November 17, 2025

Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure

Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with...

The ASCO Post

November 17, 2025

FDA Approves Ziftomenib for NPM1-Positive AML

On November 13, 2025, the U.S. Food and Drug Administration (FDA) approved ziftomenib (Komzifti), a menin inhibitor, for the treatment of adults with relapsed or refractory acute myeloid leukemia with...

The ASCO Post

November 17, 2025

Mental Health and DED

Subthreshold anxiety linked to dry eye symptoms, Chinese study finds

The Ophthalmologist